Accumulate Evidence for IP-10 in Diagnosing Pulmonary Tuberculosis

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2019 Nov 1

PMID 31666025

Citations 12

Authors

Xia Qiu

Tao Xiong

Xiaojuan Su

Yi Qu

Long Ge

Yan Yue

Yan Zeng

Wenxing Li

Peng Hu

Dezhi Mu

Affiliations

Soon will be listed here.

Abstract

Backgrounds: Pulmonary tuberculosis (PTB) is a major health and economic burden. Accurate PTB detection is an important step to eliminating TB globally. Interferon gamma-induced protein 10 (IP-10) has been reported as a potential diagnostic marker for PTB since 2007. In this study, a meta-analysis approach was used to assess diagnostic value of IP-10 for PTB.

Methods: Web of Science, PubMed, the Cochrane Library, and Embase databases were searched for studies published in English up to February 2019. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), the area under the curve (AUC) and hierarchical summary receiver operating characteristic (HSROC) curve were estimated by the HSROC model and random effect model.

Results: Eighteen studies including 2836 total participants met our inclusion criteria. The pooled sensitivity, specificity, PLR, and NLR of IP-10 for PTB detection were 86, 88%, 7.00, and 0.16, respectively. The pooled DOR was 43.01, indicating a very powerful discriminatory ability of IP-10. The AUC was 0.93 (95% CI: 0.91-0.95), showed the accuracy of IP-10 was good. Meta-regression showed that there was no heterogeneity with respect to TB burden, study design type, age, IP-10 assay method, IP-10 condition and HIV-infection status.

Conclusions: Our results showed that IP-10 is a promising marker for differentiating PTB from non-TB.

Citing Articles

Interferon (IFN)-gamma (γ) inducible protein 10 (IP-10) in the diagnosis of latent and active tuberculosis in Bacille Calmette Guerin (BCG)-vaccinated pediatric population.

Druszczynska M, Seweryn M, Wawrocki S, Pankowska A, Kulbachko A, Jurczak M PLoS One. 2025; 20(1):e0314400.

PMID: 39836665 PMC: 11750100. DOI: 10.1371/journal.pone.0314400.

A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings.

Romero-Tamarit A, Valles X, Munar-Garcia M, Espinosa-Pereiro J, Saborit N, Tortola M Infection. 2024; 52(2):611-623.

PMID: 38349459 PMC: 10954962. DOI: 10.1007/s15010-024-02184-2.

: immune response, biomarkers, and therapeutic intervention.

Zhuang L, Yang L, Li L, Ye Z, Gong W MedComm (2020). 2024; 5(1):e419.

PMID: 38188605 PMC: 10771061. DOI: 10.1002/mco2.419.

Evaluation of the mRNA release assay for diagnosis of TB in HIV-infected individuals.

Tang Y, Yu Y, Wang Q, Wen Z, Song R, Li Y Front Cell Infect Microbiol. 2023; 13:1152665.

PMID: 37333845 PMC: 10272546. DOI: 10.3389/fcimb.2023.1152665.

Evaluation of subsp. isocitrate lyase () and ABC transporter () knockout mutants as vaccine candidates.

Eshraghisamani R, Arrazuria R, Luo L, De Buck J Front Cell Infect Microbiol. 2023; 13:1149419.

PMID: 37065210 PMC: 10098363. DOI: 10.3389/fcimb.2023.1149419.

References

Blauenfeldt T, Wagner D, Aabye M, Heyckendorf J, Lange B, Lange C . Thermostability of IFN-γ and IP-10 release assays for latent infection with Mycobacterium tuberculosis: A TBnet study. Tuberculosis (Edinb). 2016; 98:7-12. DOI: 10.1016/j.tube.2015.04.013. View

Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland M, Eugen-Olsen J . Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J. 2008; 32(6):1607-15. DOI: 10.1183/09031936.00055508. View

Jeong Y, Hur Y, Lee H, Kim S, Cho J, Chang J . Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production. J Clin Microbiol. 2014; 53(2):504-10. PMC: 4298513. DOI: 10.1128/JCM.02758-14. View

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

Kabeer B, Raman B, Thomas A, Perumal V, Raja A . Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One. 2010; 5(2):e9051. PMC: 2816212. DOI: 10.1371/journal.pone.0009051. View

Zhao Y, Yang X, Zhang X, Yu Q, Zhao P, Wang J . IP-10 and RANTES as biomarkers for pulmonary tuberculosis diagnosis and monitoring. Tuberculosis (Edinb). 2018; 111:45-53. DOI: 10.1016/j.tube.2018.05.004. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias H . WHO's new end TB strategy. Lancet. 2015; 385(9979):1799-1801. DOI: 10.1016/S0140-6736(15)60570-0. View

La Manna M, Orlando V, Li Donni P, Sireci G, Di Carlo P, Cascio A . Identification of plasma biomarkers for discrimination between tuberculosis infection/disease and pulmonary non tuberculosis disease. PLoS One. 2018; 13(3):e0192664. PMC: 5854242. DOI: 10.1371/journal.pone.0192664. View

10.

Holm L, Rose M, Kimaro G, Bygbjerg I, Mfinanga S, Ravn P . A comparison of interferon-γ and IP-10 for the diagnosis of tuberculosis. Pediatrics. 2014; 134(6):e1568-75. DOI: 10.1542/peds.2014-1570. View

11.

Biraro I, Kimuda S, Egesa M, Cose S, Webb E, Joloba M . The Use of Interferon Gamma Inducible Protein 10 as a Potential Biomarker in the Diagnosis of Latent Tuberculosis Infection in Uganda. PLoS One. 2016; 11(1):e0146098. PMC: 4714877. DOI: 10.1371/journal.pone.0146098. View

12.

OGarra A, Redford P, McNab F, Bloom C, Wilkinson R, Berry M . The immune response in tuberculosis. Annu Rev Immunol. 2013; 31:475-527. DOI: 10.1146/annurev-immunol-032712-095939. View

13.

Luo J, Zhang M, Yan B, Li F, Guan S, Chang K . Diagnostic performance of plasma cytokine biosignature combination and MCP-1 as individual biomarkers for differentiating stages Mycobacterium tuberculosis infection. J Infect. 2018; 78(4):281-291. DOI: 10.1016/j.jinf.2018.10.017. View

14.

McInnes M, Moher D, Thombs B, McGrath T, Bossuyt P, Clifford T . Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018; 319(4):388-396. DOI: 10.1001/jama.2017.19163. View

15.

Guo S, Jia L, Hu Q, Long H, Pang C, Wen F . Diagnostic accuracy of interferon gamma-induced protein 10 for tuberculosis: a meta-analysis. Int J Clin Exp Med. 2014; 7(1):93-100. PMC: 3902245. View

16.

Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A . IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect. 2012; 65(1):49-59. DOI: 10.1016/j.jinf.2012.03.017. View

17.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

18.

Azzurri A, Sow O, Amedei A, Bah B, Diallo S, Peri G . IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005; 7(1):1-8. DOI: 10.1016/j.micinf.2004.09.004. View

19.

Latorre I, Diaz J, Mialdea I, Serra-Vidal M, Altet N, Prat C . IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children. J Infect. 2014; 69(6):590-9. DOI: 10.1016/j.jinf.2014.06.013. View

20.

Balcells M, Ruiz-Tagle C, Tiznado C, Garcia P, Naves R . Diagnostic performance of GM-CSF and IL-2 in response to long-term specific-antigen cell stimulation in patients with active and latent tuberculosis infection. Tuberculosis (Edinb). 2018; 112:110-119. DOI: 10.1016/j.tube.2018.08.006. View